Universities and public research institutes across the region are advancing research in cancer treatment, cell therapy, biologics and other emerging fields. The scientific foundation is growing stronger, and the region is producing a broader pipeline of discoveries with the potential to address significant healthcare challenges. The next phase of growth will depend on how effectively academic research can move from discovery into translational research, scale up and eventual commercial application.

Recent developments across the region highlight both the strength of the region’s scientific research ecosystem and the significant journey that remains to translate these discoveries into products that reach patients. Researchers at the National University of Singapore have unlocked high-resolution atomic structures of disease-related proteins, creating new pathways for targeted drug discovery against major global diseases such as malaria, tuberculosis and cancer. In Thailand, Chulalongkorn University and the Thai Red Cross have announced a collaboration to advance monoclonal antibody development towards industrial-scale manufacturing, with lung cancer as an initial priority. 

While these initiatives are at different stages of development and should not be viewed as market-ready therapies, they demonstrate the breadth of scientific ambition emerging from the region’s research institutions. More importantly, they highlight a question that is facing the region's research ecosystem: how can promising research progress beyond the laboratory and into development, manufacturing and ultimately patient impact? 

For a scientific discovery to become commercially viable, researchers must demonstrate more than scientific promise. They must show that an innovation can be reproduced consistently, scaled efficiently and supported by a credible pathway for regulation, investment and manufacturing. The greatest challenge often lies between early proof of concept and a development plan robust enough to attract the confidence of investors, startup founders, and industry partners. Consistency and reproducibility are critical for research and industry, and without that bridge, even promising discoveries can struggle to progress. 

Bridge the gap between discovery and development

Academic research and biopharma development serve different but equally important objectives.

University laboratories are designed to test hypotheses, explore scientific breakthroughs and generate new knowledge. Development teams must answer a different set of questions. Are results reproducible? Can critical inputs be sourced consistently? Will the process remain robust as production scales increase? As a result, approaches that work in small-scale experimental settings often require significant adaptation before they are ready for clinical development or commercial deployment.

For early-stage researchers, these development considerations may not be immediately apparent. Building a credible pathway requires suitable analytical methods, a clear understanding of acceptable variability, rigorous documentation that enables others to reproduce the work, and early attention to the quality and supply of critical inputs. These considerations help researchers make decisions that preserve future development options. 

The challenge becomes more pronounced when a grant-funded project begins moving towards a startup or commercial partnership. A new venture may possess promising scientific data but have limited access to process development facilities, specialized instrumentation, manufacturing expertise and regulatory support. At the same time, investors and industry partners often expect evidence of reproducibility and a credible route to scale before committing resources. This creates a common challenge across the innovation ecosystem, where startups are expected to demonstrate development readiness before they have built the capabilities needed to support it. 

As a result, projects with strong scientific foundations can stall, not because the science is weak, but because the capabilities needed to advance them have yet to be established. Closing this translational gap requires practical support at critical stages of development, including access to suitable technologies, technical guidance, shared core facilities and experts who understand how laboratory processes evolve into scalable products. 

Pair access to technology with subject matter expertise

Technology plays an essential role in accelerating innovation. However, technology alone does not solve translational challenges. What often determines success is the quality of the decisions made around its use. Researchers must make critical decisions on analytical methods, experimental design and process development long before a project reaches scale-up. These early decisions can have a significant impact on the long-term viability of a program. 

This is where access to the right technologies, expertise and development support becomes especially important. 

The growing ecosystem of shared core facilities and reference site set up across academia is expanding access to advanced technologies, established workflows, later-stage methods and local expertise. This aligns with findings from Cytiva’s 2025 Biopharma Index, where both the R&D ecosystem and talent pool emerged as important factors in strengthening biopharma capability. 

Through its collaborations with academic institutions across Southeast Asia, Cytiva has seen that researchers often need more than access to equipment. They need training, application support and technical guidance that help them generate robust data, interpret results effectively and make informed development decisions. This approach is reflected in Cytiva's work with universities supporting access to surface plasmon resonance (SPR) technology and its applications. SPR enables real-time, label-free measurement of molecular interactions, providing insights into affinity, binding kinetics, specificity and mechanism of action. These capabilities support activities across the drug discovery continuum, from target validation and lead optimization to biologics development. Equally important, they help researchers strengthen the analytical capabilities needed to generate reproducible evidence and make more confident decisions as projects progress towards development.

Building talent pipelines for translation

Translational capability ultimately depends on people. Southeast Asia needs talent that can operate across scientific disciplines and development stages, including application scientists, process specialists and technical leaders who can assemble the right expertise around a promising idea. 

Researchers who understand how experimental design, process variability and analytical measurements influence outcomes are often better positioned to conduct rigorous and impactful research. The same capabilities that support successful translation also strengthen scientific quality, improve reproducibility and increase confidence in research findings. 

These capabilities are built through hands on experience. Understanding the principles of protein purification is very different from troubleshooting a workflow, evaluating variability between runs or determining which measurements are most relevant to a development decision. It is through these experiences that scientists develop the judgement needed to navigate technical and operational trade-offs. This is why talent development must extend beyond classroom learning. Universities and industry both have a role to play through guest lectures, hands-on workshops, technical seminars and collaborative research programs. These experiences expose students and early-career researchers to the practical realities of reproducibility, process design, scale-up and data interpretation, without requiring every participant to pursue a commercial career.

Cytiva has worked closely with universities to support this learning journey. Through technical workshops, collaborative projects and educational programs, researchers gain exposure to current technologies and their applications in both research and industry settings. This includes contributions to a master’s coursework program with a university in Singapore, helping students build a stronger understanding of the technologies, skills and decision-making processes that underpin modern biopharma development. Initiatives such as these play a critical role in shaping the development of the next generation of scientists.

Design the framework, not just the collaboration

As scientific programs become more complex, no single institution can provide every capability required for translation. Researchers, industry, research institutes and government agencies increasingly depend on one another to move discoveries forward. 

The question is therefore not whether collaboration is needed, but how it is structured. Translational success depends on how effectively knowledge, capabilities and responsibilities move from one stage of development to the next.  Designing an effective framework requires clear pathways for knowledge transfer, capability development and decision-making as projects mature. It also requires technical risks to be identified early and development milestones to be clearly defined. 

This is often where thoughtful collaboration makes the greatest difference.

Translational ecosystems must be designed around local needs and capabilities rather than assuming a single model will work across every market. Singapore benefits from a relatively mature ecosystem that includes universities, public research agencies, startups, shared infrastructure and industry partners. Elsewhere in Southeast Asia, research organizations are progressing within different operating environments and with varying levels of access to specialized technologies, development expertise and technical support. 

This diversity is a strength. Different countries and institutions will naturally develop expertise in different areas, creating opportunities for regional collaboration and knowledge sharing. However, such collaboration is most effective when it complements strong local capability rather than replaces it.

Effective translation therefore requires more than connecting organizations across the region. It requires practical mechanisms that allow knowledge, technology and experience to move efficiently between institutions while continuing to build local research capacity. The strongest innovation ecosystems are not necessarily those with the highest concentration of expertise, but the ones that make expertise accessible, enable capability to spread, and give promising discoveries a clearer path forward. 

From discovery to impact 

As Southeast Asia expands its capabilities in biologics, cell therapy and other advanced modalities, translational readiness will become increasingly important. Understanding future development requirements earlier can influence experimental design, analytical strategies, collaboration models and research priorities. It can also help researchers generate evidence that supports not only publication, but future development and scale-up decisions. 

The importance of translational capability will only grow as researchers explore emerging modalities such as cell and gene therapies, RNA-based medicines, antibody-drug conjugates, bispecific antibodies and other advanced biologics. These innovations hold significant promise, but they also place greater demands on analytical expertise, specialized infrastructure and closer multidisciplinary collaboration. 

Collaboration should therefore be structured to build lasting capability. Technical seminars and workshops can create awareness, but capability is built through sustained engagement that enables researchers to apply knowledge, refine approaches, and solve real-world challenges.

Southeast Asia already has many of the ingredients required for success. The priority now is to ensure that promising discoveries can move more efficiently through the next stages of development. When these elements come together, the path from discovery to development becomes clearer, stronger and more reliable. By strengthening translational pathways today, Southeast Asia can convert scientific excellence into sustainable biopharma innovation and accelerate the translation of research into therapies, technologies and capabilities that create lasting value for patients and healthcare systems across the region.